Matches in SemOpenAlex for { <https://semopenalex.org/work/W2102056560> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W2102056560 endingPage "108" @default.
- W2102056560 startingPage "108" @default.
- W2102056560 abstract "%JRAMIN HAS been reported as an anticancer agent [ 1, 21, either alone or in combination. Suramin modifies growth factor transduction within cells by binding to, and therefore blocking, certain growth factor receptors (e.g. epidermal growth factor [EGF] and transforming growth factor-alpha [TGF-a]) [3, 41. Suramin also inhibits phosphoinositide resynthesis [4] and reverse transcriptase [S] . Furthermore, suramin increases differentiation in several human tumour cell lines [6, 71. Kwok and Sutherland [8] found that adding EGF in vitro to CaSKI human squamous cancer cells sensitised them to X-rays, and radiosensitisation has been reported in WiDR human colon cancer cells treated with TGF-a [J.L. et al.]. EGF and TGF-a bind to the same receptor, and probably exert their radiosensitising effects via the same signal transduction pathway. Therefore, blocking receptors might lead to a decrease in the effectiveness of radiation treatment. Notwithstanding, compounds inducing tumour cell differentiation often increase radiosensitivity [9]. Suramin has a long half-life, and might persist at sufficient concentrations to modify radiation response [lo]. The drug is associated with the nervous system, kidney, liver, and skin, tissues which would be included in many radiation treatment fields [lo]. We studied the effect of suramin, TGF-(r and X-ray on HCT8 human colon cancer cells [ 111. This line has about lo4 receptors for EGF/TGF-a per cell, and significant radiosensitisation is found at around 100 ngiml TGF-a, which increases at 100-200 ng/ml. When suramin was added to the cultures, growth was inhibited starting at about 30 ngiml. 40 and.250 ng/ml suramin were required to inhibit tumour cell growth by 10 or 50% of control values, respectively. We investigated the effects of 30 ng/ml of suramin, so that modification of HCT-8 tumour cell radiosensitivity by suramin could be interpreted unconfounded by potential cell selection or cell cycle effects. Three protocols were used. First, suramin was added to HCT8 cells 24 h before X-ray. Flasks were briefly placed on ice," @default.
- W2102056560 created "2016-06-24" @default.
- W2102056560 creator A5060000778 @default.
- W2102056560 creator A5063499314 @default.
- W2102056560 date "1991-01-01" @default.
- W2102056560 modified "2023-09-26" @default.
- W2102056560 title "Suramin and tumour cell radiosensitivity" @default.
- W2102056560 cites W1482754811 @default.
- W2102056560 cites W1967642037 @default.
- W2102056560 cites W1995671386 @default.
- W2102056560 cites W2060747358 @default.
- W2102056560 cites W2242063705 @default.
- W2102056560 cites W2326579393 @default.
- W2102056560 cites W4302384658 @default.
- W2102056560 doi "https://doi.org/10.1016/0277-5379(91)90074-n" @default.
- W2102056560 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1826431" @default.
- W2102056560 hasPublicationYear "1991" @default.
- W2102056560 type Work @default.
- W2102056560 sameAs 2102056560 @default.
- W2102056560 citedByCount "7" @default.
- W2102056560 crossrefType "journal-article" @default.
- W2102056560 hasAuthorship W2102056560A5060000778 @default.
- W2102056560 hasAuthorship W2102056560A5063499314 @default.
- W2102056560 hasConcept C126322002 @default.
- W2102056560 hasConcept C170493617 @default.
- W2102056560 hasConcept C206684579 @default.
- W2102056560 hasConcept C2776182878 @default.
- W2102056560 hasConcept C502942594 @default.
- W2102056560 hasConcept C509974204 @default.
- W2102056560 hasConcept C71924100 @default.
- W2102056560 hasConcept C86803240 @default.
- W2102056560 hasConceptScore W2102056560C126322002 @default.
- W2102056560 hasConceptScore W2102056560C170493617 @default.
- W2102056560 hasConceptScore W2102056560C206684579 @default.
- W2102056560 hasConceptScore W2102056560C2776182878 @default.
- W2102056560 hasConceptScore W2102056560C502942594 @default.
- W2102056560 hasConceptScore W2102056560C509974204 @default.
- W2102056560 hasConceptScore W2102056560C71924100 @default.
- W2102056560 hasConceptScore W2102056560C86803240 @default.
- W2102056560 hasIssue "1" @default.
- W2102056560 hasLocation W21020565601 @default.
- W2102056560 hasLocation W21020565602 @default.
- W2102056560 hasOpenAccess W2102056560 @default.
- W2102056560 hasPrimaryLocation W21020565601 @default.
- W2102056560 hasRelatedWork W2001451863 @default.
- W2102056560 hasRelatedWork W2102056560 @default.
- W2102056560 hasRelatedWork W2220174806 @default.
- W2102056560 hasRelatedWork W2727389492 @default.
- W2102056560 hasRelatedWork W2768853417 @default.
- W2102056560 hasRelatedWork W2914811959 @default.
- W2102056560 hasRelatedWork W2947936707 @default.
- W2102056560 hasRelatedWork W3082203085 @default.
- W2102056560 hasRelatedWork W3085894646 @default.
- W2102056560 hasRelatedWork W4226195220 @default.
- W2102056560 hasVolume "27" @default.
- W2102056560 isParatext "false" @default.
- W2102056560 isRetracted "false" @default.
- W2102056560 magId "2102056560" @default.
- W2102056560 workType "article" @default.